Cited by 1,463Lipoproteins and Cardiovascular HealthPharmacovigilance and Adverse Drug ReactionsMuscle and Compartmental Disorders

The DOI matches its Crossref record; 103 of the 114 references it cites were found in a registry or an index.

Statin-Associated Myopathy

Thompson, Paul D., Clarkson, Priscilla, Karas, Richard H.·2003·JAMA

DOI 10.1001/jama.289.13.1681

Open this paper in CoChat — free account

Abstract

Statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) are associated with skeletal muscle complaints, including clinically important myositis and rhabdomyolysis, mild serum creatine kinase (CK) elevations, myalgia with and without elevated CK levels, muscle weakness, muscle cramps, and persistent myalgia and CK elevations after statin withdrawal. We performed a literature review to provide a clinical summary of statin-associated myopathy and discuss possible mediating mechanisms. We also update the US Food and Drug Administration (FDA) reports on statin-associated rhabdomyolysis. Articles on statin myopathy were identified via a PubMed search through November 2002 and articles on statin clinical trials, case series, and review articles were identified via a PubMed search through January 2003. Adverse event reports of statin-associated rhabdomyolysis were also collected from the FDA MEDWATCH database. The literature review found that reports of muscle problems during statin clinical trials are extremely rare. The FDA MEDWATCH Reporting System lists 3339 cases of statin-associated rhabdomyolysis reported between January 1, 1990, and March 31, 2002. Cerivastatin was the most commonly implicated statin. Few data are available regarding the frequency of less-serious events such as muscle pain and weakness, which may affect 1% to 5% of patients. The risk of rhabdomyolysis and other adverse effects with statin use can be exacerbated by several factors, including compromised hepatic and renal function, hypothyroidism, diabetes, and concomitant medications. Medications such as the fibrate gemfibrozil alter statin metabolism and increase statin plasma concentration. How statins injure skeletal muscle is not clear, although recent evidence suggests that statins reduce the production of small regulatory proteins that are important for myocyte maintenance.

Integrity signals

Registry

Crossref · 10.1001/jama.289.13.1681

Cites

103 of 103 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial
(2002) · The Lancet · doi:10.1016/s0140-6736(02)09327-3 · Cited by 6,992
Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol Levels: Results of AFCAPS/TexCAPS
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
SCANDINAVIANSIMVASTATINSURVIVAL (1994) · The Lancet · doi:10.1016/s0140-6736(94)90566-5 · Cited by 3,638
PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA
Hepherd, J. A. S., Obbe, S. T. M. C., Ord, I. A. F., Sles, C. H. G. I., Orimer, A. R. O. L., Acfarlane, P. E. W. M., Illop, J. A. H. M. C. K., Ackard, C. H. J. P., & Roup, S. T. G. (1995) · Cited by 3,453

Show all 114 references

Research works printed but not linked: 9

Fuhrmans, 2002, Bayer discloses higher death toll from Baycol., Wall Street Journal, A10
Hamilton-Craig, 2001, Statin-associated myopathy., Med J Aust, 175, 486, 10.5694/mja2.2001.175.issue-9 · DOI
Omar, 2002, FDA adverse event reports on statin-associated rhabdomyolysis., Ann Pharmacother, 36, 288, 10.1345/aph.1A289 · DOI · Paper page
GISSI Prevenzione Investigators, 2000, Results of the low-dose (20 mg) pravastatin GISSI Prevenzione trial in 4271 patients with recent myocardial infarction: do stopped trials contribute to overall knowledge (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico)?, Ital Heart J, 1, 810
Omar, 2001, Rhabdomyolysis and HMG-CoA reductase inhibitors., Ann Pharmacother, 35, 1096, 10.1345/aph.10228 · DOI · Paper page
Shek, 2001, Statin-fibrate combination therapy., Ann Pharmacother, 35, 908, 10.1345/aph.10315 · DOI · Paper page
Prueksaritanont, 2002, Metabolic interactions between gemfibrozil and statins in human liver preparations [abstract]., Circulation, 106, II185
Not Available, 2001, Cardiovascular Trials Review
Not Available, 2002, Cardiovascular Trials Review

Sorted by citations

Items 101–200 of 1,001

Plasma metabolomic profiles enhance precision medicine for volunteers of normal health
Guo, L., Milburn, M. V., Ryals, J. A., Lonergan, S. C., Mitchell, M. W., Wulff, J. E., Alexander, D. C., Evans, A. M., Bridgewater, B., Miller, L. A. D., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1508425112 · Cited by 176
Toward “Pain-Free” Statin Prescribing: Clinical Algorithm for Diagnosis and Management of Myalgia
Jacobson, T. A. (2008) · Mayo Clinic Proceedings · doi:10.4065/83.6.687 · Cited by 170
The Safety of Rosuvastatin as Used in Common Clinical Practice
Alsheikh-Ali, A. A. A., Ambrose, M. S., Kuvin, J. T., & Karas, R. H. (2005) · Circulation · doi:10.1161/circulationaha.105.555482 · Cited by 166
Self-citation
Lipin-1 regulates autophagy clearance and intersects with statin drug effects in skeletal muscle
Zhang, P., Verity, M. A., & Reue, K. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.05.003 · Cited by 166
Association between statin-associated myopathy and skeletal muscle damage
Mohaupt, M. G., Karas, R. H., Babiychuk, E. B., Sanchez-Freire, V., Monastyrskaya, K., Iyer, L., Hoppeler, H., Breil, F., & Draeger, A. (2009) · Canadian Medical Association Journal · doi:10.1503/cmaj.081785 · Cited by 166
Self-citation
Simvastatin Effects on Skeletal Muscle
Larsen, S., Stride, N., Hey-Mogensen, M., Hansen, C. N., Bang, L. E., Bundgaard, H., Nielsen, L. B., Helge, J. W., & Dela, F. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.09.036 · Cited by 165
SLCO1B1 (OATP1B1, an Uptake Transporter) and ABCG2 (BCRP, an Efflux Transporter) Variant Alleles and Pharmacokinetics of Pitavastatin in Healthy Volunteers
Ieiri, I., Suwannakul, S., Maeda, K., Uchimaru, H., Hashimoto, K., Kimura, M., Fujino, H., Hirano, M., Kusuhara, H., Irie, S., et al. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100190 · Cited by 164
Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia
Draeger, A., Monastyrskaya, K., Mohaupt, M., Hoppeler, H., Savolainen, H., Allemann, C., & Babiychuk, E. (2006) · The Journal of Pathology · doi:10.1002/path.2018 · Cited by 163
Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel: This paper is also published in parallel in Archives of Medical Science [Banach M, Rizzo M, Toth PP, et al. Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Arch Med Sci 2015; 11(1): 1–23]
Banach, M., Rizzo, M., Toth, P. P., Farnier, M., Davidson, M. H., Al-Rasadi, K., Aronow, W. S., Athyros, V., Djuric, D. M., Ezhov, M. V., et al. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.1039980 · Cited by 162
Clinical implications of pharmacogenomics of statin treatment
Mangravite, L. M., Thorn, C. F., & Krauss, R. M. (2006) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500384 · Cited by 164
Prevalence of Musculoskeletal Pain and Statin Use
Buettner, C., Davis, R. B., Leveille, S. G., Mittleman, M. A., & Mukamal, K. J. (2008) · Journal of General Internal Medicine · doi:10.1007/s11606-008-0636-7 · Cited by 159
Toxic and drug-induced myopathies
Dalakas, M. C. (2009) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2008.168294 · Cited by 157
Simvastatin triggers mitochondria-induced Ca2+ signaling alteration in skeletal muscle
Sirvent, P., Mercier, J., Vassort, G., & Lacampagne, A. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.02.070 · Cited by 154
Tolerability of Red Yeast Rice (2,400 mg Twice Daily) Versus Pravastatin (20 mg Twice Daily) in Patients With Previous Statin Intolerance
Halbert, S. C., French, B., Gordon, R. Y., Farrar, J. T., Schmitz, K., Morris, P. B., Thompson, P. D., Rader, D. J., & Becker, D. J. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.08.672 · Cited by 154
Self-citation
Hypothyroidism and dyslipidemia: Modern concepts and approaches
Pearce, E. N. (2004) · Current Cardiology Reports · doi:10.1007/s11886-004-0054-3 · Cited by 153
Distribution of creatine kinase in the general population: Implications for statin therapy
Brewster, L. M., Mairuhu, G., Sturk, A., & van Montfrans, G. A. (2007) · American Heart Journal · doi:10.1016/j.ahj.2007.06.008 · Cited by 150
Statins induce apoptosis in rat and human myotube cultures by inhibiting protein geranylgeranylation but not ubiquinone
Johnson, T. E. (2004) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2004.04.010 · Cited by 146
Myoglobin causes oxidative stress, increase of NO production and dysfunction of kidney's mitochondria
Plotnikov, E. Y., Chupyrkina, A. A., Pevzner, I. B., Исаев, Н. К., & Zorov, D. B. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.06.005 · Cited by 142
SLCO1B1 Variants and Statin-Induced Myopathy — A Genomewide Study
Act, A. (2008) · Cited by 142
Statins and Pulmonary Fibrosis: The Potential Role of NLRP3 Inflammasome Activation
Xu, J., Washko, G. R., Nakahira, K., Hatabu, H., Patel, A. S., Fernandez, I. E., Nishino, M., Okajima, Y., Yamashiro, T., Ross, J. C., et al. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201108-1574oc · Cited by 140
Safety of rosuvastatin
Shepherd, J., Hunninghake, D. B., Stein, E. A., Kastelein, J. J. P., Harris, S., Pears, J. S., & Hutchinson, H. G. (2004) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2004.06.049 · Cited by 137
Pharmacogenetics and Cardiovascular Disease—Implications for Personalized Medicine
Johnson, J. A., & Cavallari, L. H. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.007252 · Cited by 141
Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several-fold in patients with atorvastatin-induced myopathy
HERMANN, M., Bogsrud, M. P., Molden, E., Åsberg, A., Mohebi, B. U., Ose, L., & Retterstøl, K. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.02.014 · Cited by 138
Pitavastatin: Efficacy and Safety Profiles of A Novel Synthetic HMG‐CoA Reductase Inhibitor
Kajinami, K., Takekoshi, N., & Saito, Y. (2003) · Cardiovascular Drug Reviews · doi:10.1111/j.1527-3466.2003.tb00116.x · Cited by 136
Safety of perioperative statin use in high-risk patients undergoing major vascular surgery
Schouten, O., Kertai, M. D., Bax, J. J., Durazzo, A., Biagini, E., Boersma, E. H., van Waning, V. H., Lameris, T. W., van Sambeek, M. R. H. M., & Poldermans, D. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2004.10.046 · Cited by 134
Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damage
Wilke, R. A., Moore, J. H., & Burmester, J. K. (2005) · Pharmacogenetics and Genomics · doi:10.1097/01213011-200506000-00007 · Cited by 133
Evaluation of ubiquinone concentration and mitochondrial function relative to cerivastatin-induced skeletal myopathy in rats
Schaefer, W. H., Lawrence, J. W., Loughlin, A. F., Stoffregen, D. A., Mixson, L. A., Dean, D. C., Raab, C. E., Yu, N. X., Lankas, G. R., & Frederick, C. B. (2003) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2003.08.013 · Cited by 131
Elevated serum creatine phosphokinase in choline-deficient humans: mechanistic studies in C2C12 mouse myoblasts
da Costa, K.-A., Badea, M., Fischer, L. M., & Zeisel, S. H. (2004) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/80.1.163 · Cited by 130
Statins and Musculoskeletal Conditions, Arthropathies, and Injuries
Mansi, I. A., Frei, C. R., Pugh, M. J., Makris, U. E., & Mortensen, E. M. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.6184 · Cited by 131
Predictors of mortality in patients with suspected propofol infusion syndrome
Fong, J. J., Sylvia, L. M., Ruthazer, R., Schumaker, G. L., Kcomt, M., & Devlin, J. W. (2008) · Critical Care Medicine · doi:10.1097/ccm.0b013e318180c1eb · Cited by 128
Association of Patient Perceptions of Cardiovascular Risk and Beliefs on Statin Drugs With Racial Differences in Statin Use: Insights From the Patient and Provider Assessment of Lipid Management Registry
Nanna, M. G., Navar, A. M., Zakroysky, P., Xiang, Q., Goldberg, A. C., Robinson, J., Roger, V. L., Virani, S. S., Wilson, P. W. F., Elassal, J., et al. (2018) · JAMA Cardiology · doi:10.1001/jamacardio.2018.1511 · Cited by 122
Influence of Drug Transporter Polymorphisms on Pravastatin Pharmacokinetics in Humans
Kivistö, K. T., & Niemi, M. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-9159-2 · Cited by 130
Risk factors for statin‐associated rhabdomyolysis
Schech, S. D., Graham, D. J., Staffa, J. A., Andrade, S. E., Grenade, L. L., Burgess, M., Blough, D. K., Stergachis, A. S., Chan, K. A., Platt, R. G., et al. (2006) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1287 · Cited by 125
Primary and secondary coenzyme Q10 deficiency: the role of therapeutic supplementation
Potgieter, M., Pretorius, E., & Pepper, M. S. (2013) · Nutrition Reviews · doi:10.1111/nure.12011 · Cited by 124
Race, ethnicity, and sociocultural characteristics predict noncompliance with lipid-lowering medications
Kaplan, R. C., Bhalodkar, N. C., Brown, E. J., White, J. R., & Brown, D. L. (2004) · Preventive Medicine · doi:10.1016/j.ypmed.2004.04.041 · Cited by 121
Inappropriate Medication Use and Prescribing Indicators in Elderly Australians
Basger, B., Chen, T. F., & Moles, R. J. (2008) · Drugs & Aging · doi:10.2165/00002512-200825090-00004 · Cited by 120
Blunted Akt/FOXO signalling and activation of genes controlling atrophy and fuel use in statin myopathy
Mallinson, J. E., Constantin‐Teodosiu, D., Sidaway, J. E., Westwood, F. R., & Greenhaff, P. L. (2008) · The Journal of Physiology · doi:10.1113/jphysiol.2008.164699 · Cited by 119
Squalene synthase: a critical enzyme in the cholesterol biosynthesis pathway
Do, R., Kiss, R., Gaudet, D., & Engert, J. C. (2008) · Clinical Genetics · doi:10.1111/j.1399-0004.2008.01099.x · Cited by 118
Reduction of Serum Ubiquinol-10 and Ubiquinone-10 Levels by Atorvastatin in Hypercholesterolemic Patients
Mabuchi, H., Higashikata, T., Kawashiri, M., Katsuda, S., Mizuno, M., Nohara, A., Inazu, A., Koizumi, J., & Kobayashi, J. (2005) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.12.111 · Cited by 119
Drug Interactions of Medications Commonly Used in Diabetes
Triplitt, C. L. (2006) · Diabetes Spectrum · doi:10.2337/diaspect.19.4.202 · Cited by 131
Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population
Pasanen, M. K., Backman, J. T., Neuvonen, P. J., & Niemi, M. (2006) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-006-0123-1 · Cited by 119
Statin-Induced Rhabdomyolysis: A Comprehensive Review of Case Reports
Mendes, P. L., Robles, P., & Mathur, S. (2013) · Physiotherapy Canada · doi:10.3138/ptc.2012-65 · Cited by 119
The genetics of statin-induced myopathy
Ghatak, A., Faheem, O., & Thompson, P. D. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.11.033 · Cited by 118
Self-citation
The role of fibrates in managing hyperlipidemia: Mechanisms of action and clinical efficacy
Fazio, S., & Linton, M. F. (2004) · Current Atherosclerosis Reports · doi:10.1007/s11883-004-0104-8 · Cited by 118
A Comprehensive Description of Muscle Symptoms Associated with Lipid-Lowering Drugs
Franc, S., Dejager, S., Bruckert, É., Chauvenet, M., Giral, P., & Turpin, G. (2003) · Cardiovascular Drugs and Therapy · doi:10.1023/b:card.0000015861.26111.ab · Cited by 117
Statin‐induced muscle damage and atrogin‐1 induction is the result of a geranylgeranylation defect
Cao, P., Hanai, J., Tanksale, P., Imamura, S., Sukhatme, V. P., & Lecker, S. H. (2009) · The FASEB Journal · doi:10.1096/fj.08-128843 · Cited by 117
A Drug Screen using Human iPSC-Derived Hepatocyte-like Cells Reveals Cardiac Glycosides as a Potential Treatment for Hypercholesterolemia
Cayo, M. A., Mallanna, S. K., Furio, F. D., Jing, R., Tolliver, L. B., Bures, M., Urick, A., Noto, F. K., Pashos, E. E., Greseth, M. D., et al. (2017) · Cell stem cell · doi:10.1016/j.stem.2017.01.011 · Cited by 115
Molecular Mechanisms of Muscle Fatigue
Constantin‐Teodosiu, D., & Constantin, D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111587 · Cited by 134
Molecular basis of statin-associated myopathy
Vaklavas, C., Chatzizisis, Y. S., Ziakas, A., Zamboulis, C., & Giannoglou, G. D. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.05.021 · Cited by 115
Simvastatin impairs ADP-stimulated respiration and increases mitochondrial oxidative stress in primary human skeletal myotubes
Kwak, H.-B., Thalacker-Mercer, A., Anderson, E. J., Lin, C.-T., Kane, D. A., Lee, N.-S., Cortright, R. N., Bamman, M. M., & Neufer, P. D. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.10.449 · Cited by 114
Statin‐Associated Muscle‐Related Adverse Effects: A Case Series of 354 Patients
Cham, S., Evans, M. A., Denenberg, J. O., & Golomb, B. A. (2010) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.30.6.541 · Cited by 114
Effects of Statins on Skeletal Muscle: A Perspective for Physical Therapists
Stasi, S. L. D., MacLeod, T. D., Winters, J. D., & Binder‐Macleod, S. A. (2010) · Physical Therapy · doi:10.2522/ptj.20090251 · Cited by 114
Statin safety: an appraisal from the adverse event reporting system
Davidson, M. H., Clark, J. A., Glass, L. M., & Kanumalla, A. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.12.008 · Cited by 113
Statins Neuromuscular Adverse Effects
Attardo, S., Musumeci, O., Velardo, D., & Toscano, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158364 · Cited by 114
The clinical use of HMG CoA‐reductase inhibitors and the associated depletion of coenzyme Q 10 . A review of animal and human publications
Langsjoen, P. H., & Langsjoen, A. M. (2003) · BioFactors · doi:10.1002/biof.5520180212 · Cited by 112
Mechanisms and assessment of statin‐related muscular adverse effects
Moßhammer, D., Schaeffeler, E., Schwab, M. G., & Mörike, K. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12360 · Cited by 112
Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease – a perspective
KONES, R. J. (2010) · Drug Design Development and Therapy · doi:10.2147/dddt.s10812 · Cited by 112
Selenoproteins, Cholesterol-Lowering Drugs, and the Consequences Revisiting of the Mevalonate Pathway
Moosmann, B., & Behl, C. (2004) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2004.08.003 · Cited by 111
Rhabdomyolysis associated with hydroxymethylglutaryl-coenzyme A reductase inhibitors
Jamal, S. M., Eisenberg, M. J., & Christopoulos, S. (2004) · American Heart Journal · doi:10.1016/j.ahj.2003.12.037 · Cited by 111
Introducing the ‘Drucebo’ effect in statin therapy: a systematic review of studies comparing reported rates of statin‐associated muscle symptoms, under blinded and open‐label conditions
Penson, P. E., Mancini, G. B. J., Toth, P. P., Martin, S. S., Watts, G. F., Sahebkar, A., Mikhailidis, D. P., Banach, M., & on behalf of Lipid and Blood Pressure Meta‐Analysis Collaboration (LBPMC) Group & International Lipid Expert Panel (ILEP) (2018) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12344 · Cited by 110
Posttranslational Regulation of HMG CoA Reductase, the Rate-Limiting Enzyme in Synthesis of Cholesterol
Schumacher, M. M., & DeBose‐Boyd, R. A. (2021) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-081820-101010 · Cited by 119
Long-term effects of nutraceuticals (berberine, red yeast rice, policosanol) in elderly hypercholesterolemic patients
Marazzi, G., Cacciotti, L., Pelliccia, F., Iaia, L., Volterrani, M., Caminiti, G., Sposato, B., Massaro, R., Grieco, F., & Rosano, G. (2011) · Advances in Therapy · doi:10.1007/s12325-011-0082-5 · Cited by 107
Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20 536 people
Collaborative, H. P. S. (2006) · BMJ · doi:10.1136/bmj.38993.731725.be · Cited by 109
Interactions of Human P-glycoprotein with Simvastatin, Simvastatin Acid, and Atorvastatin
Hochman, J. H., Pudvah, N. T., Qiu, J., Yamazaki, M., Tang, C., Lin, J. H., & Prueksaritanont, T. (2004) · Pharmaceutical Research · doi:10.1023/b:pham.0000041466.84653.8c · Cited by 109
The relationship of vitamin D deficiency to statin myopathy
Gupta, A., & Thompson, P. D. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.11.039 · Cited by 108
Self-citation
Review: Immune‐mediated necrotizing myopathies – a heterogeneous group of diseases with specific myopathological features
Stenzel, W., Goebel, H. H., & Aronica, E. (2012) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2012.01302.x · Cited by 106
High-Dose Statins in Acute Coronary Syndromes
Nissen, S. E. (2004) · JAMA · doi:10.1001/jama.292.11.1365 · Cited by 104
Safety of statins: an update
Hu, M., Cheung, B. M. Y., & Tomlinson, B. (2012) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098612439884 · Cited by 107
Statin use and musculoskeletal pain among adults with and without arthritis
Buettner, C., Rippberger, M. J., Smith, J. K., Leveille, S. G., Davis, R. B., & Mittleman, M. A. (2012) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.08.007 · Cited by 102
Statin intolerance because of myalgia, myositis, myopathy, or myonecrosis can in most cases be safely resolved by vitamin d supplementation
Glueck, C. J., Pandit, R., Kumar, A., Wang, P., Khayznikov, M., & Hemachrandra, K. (2015) · North American Journal of Medical Sciences · doi:10.4103/1947-2714.153919 · Cited by 102
Correlates of Fatigue in Patients With Heart Failure
Evangelista, L. S., Moser, D. K., Westlake, C. A., Pike, N. A., Ter‐Galstanyan, A., & Dracup, K. (2008) · Progress in Cardiovascular Nursing · doi:10.1111/j.1751-7117.2008.07275.x · Cited by 102
Cardiovascular Risk and Statin Therapy Considerations in Women
Gheorghe, G., Toth, P. P., BUNGAU, S. G., Behl, T., Ilie, M., Stoian, A. P., Bratu, O. G., Bacalbaşa, N., Rus, M., & Diaconu, C. C. (2020) · Diagnostics · doi:10.3390/diagnostics10070483 · Cited by 106
Apoptotic injury in cultured human hepatocytes induced by HMG-CoA reductase inhibitors
Kubota, T., Fujisaki, K., Itoh, Y., Yano, T., Sendo, T., & Oishi, R. (2004) · Biochemical Pharmacology · doi:10.1016/j.bcp.2004.02.037 · Cited by 100
Statin‐associated myopathy and its exacerbation with exercise
Meador, B. M., & Huey, K. A. (2010) · Muscle & Nerve · doi:10.1002/mus.21817 · Cited by 99
Isoprenoid metabolism and the pleiotropic effects of statins
Laufs, U., & Liao, J. K. (2003) · Current Atherosclerosis Reports · doi:10.1007/s11883-003-0008-z · Cited by 100
Colesevelam HCl: a non-systemic lipid-altering drug
Bays, H. E., & Dujovne, C. A. (2003) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.4.5.779 · Cited by 98
Safety considerations for statins
Bolego, C., Baetta, R., Bellosta, S., Corsini, A., & Paoletti, R. (2002) · Current Opinion in Lipidology · doi:10.1097/00041433-200212000-00007 · Cited by 98
Can statins reduce perioperative morbidity and mortality in patients undergoing non-cardiac vascular surgery?
Paraskevas, K. I., Liapis, C. D., Hamilton, G., & Mikhailidis, D. P. (2006) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2006.03.009 · Cited by 97
Effect of Statins on Creatine Kinase Levels Before and After a Marathon Run
Parker, B. A., Augeri, A. L., Capizzi, J. A., Ballard, K. D., Troyanos, C., Baggish, A. L., d’Hemecourt, P. A., & Thompson, P. D. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2011.08.045 · Cited by 98
Self-citation
Hepatic Basolateral Efflux Contributes Significantly to Rosuvastatin Disposition I: Characterization of Basolateral Versus Biliary Clearance Using a Novel Protocol in Sandwich-Cultured Hepatocytes
Pfeifer, N. D., Yang, K., & Brouwer, K. L. R. (2013) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.207472 · Cited by 97
A Novel Variant Allele of OATP-C (SLCO1B1) Found in a Japanese Patient with Pravastatin-induced Myopathy
Morimoto, K., Oishi, T., Ueda, S., Ueda, M., Hosokawa, M., & Chiba, K. (2004) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.19.453 · Cited by 96
Damage and the repeated bout effect of arm, leg, and trunk muscles induced by eccentric resistance exercises
Chen, T. C., Yang, T., Huang, M.-J., Wang, H., Tseng, K., Chen, H.-L., & Nosaka, K. (2019) · Scandinavian Journal of Medicine and Science in Sports · doi:10.1111/sms.13388 · Cited by 96
Statin-induced myositis: a commonly encountered or rare side effect?
Mukhtar, R., & Reckless, J. P. D. (2005) · Current Opinion in Internal Medicine · doi:10.1097/01.mol.0000188414.90528.71 · Cited by 93
Myotoxicity associated with lipid-lowering drugs
Baer, A. N., & Wortmann, R. L. (2006) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e328010c559 · Cited by 93
The Effect of HMG-CoA Reductase Inhibitors on Coenzyme Q10: Possible Biochemical/Clinical Implications
Hargreaves, I. P., Duncan, A. J., Heales, S. J. R., & Land, J. M. (2005) · Drug Safety · doi:10.2165/00002018-200528080-00002 · Cited by 91
Deletion of the Selenocysteine tRNA Gene in Macrophages and Liver Results in Compensatory Gene Induction of Cytoprotective Enzymes by Nrf2
Suzuki, T., Kelly, V. P., Motohashi, H., Nakajima, O., Takahashi, S., Nishimura, S., & Yamamoto, M. P. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m708352200 · Cited by 92
Muscle mitochondrial metabolism and calcium signaling impairment in patients treated with statins
Sirvent, P., Fabre, O., Bordenave, S., Hillaire-Buys, D., Raynaud De Mauverger, E., Lacampagne, A., & Mercier, J. (2012) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2012.01.008 · Cited by 90
Statin myopathy: Incidence, risk factors, and pathophysiology
Sewright, K. A., Clarkson, P. M., & Thompson, P. D. (2007) · Current Atherosclerosis Reports · doi:10.1007/s11883-007-0050-3 · Cited by 90
Self-citation
Muscular effects of statins in the elderly female: a review
Schneider, E. B., Bhardwaj, & Selvarajah, S. (2013) · Clinical Interventions in Aging · doi:10.2147/cia.s29686 · Cited by 90
Pharmacogenomics of statins: understanding susceptibility to adverse effects
Kitzmiller, J., Mikulik, E., Dauki, A. M., Mukherjee, C., & Luzum, J. A. (2016) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s86013 · Cited by 92
Unmet Needs in LDL-C Lowering: When Statins Won’t Do!
Krähenbühl, S., Pavik-Mezzour, I., & von Eckardstein, A. (2016) · Drugs · doi:10.1007/s40265-016-0613-0 · Cited by 89
Skeletal muscle-specific HMG-CoA reductase knockout mice exhibit rhabdomyolysis: A model for statin-induced myopathy
Osaki, Y., Nakagawa, Y., Miyahara, S., IWASAKI, H. O., Ishii, A., Matsuzaka, T., Kobayashi, K., Yatoh, S., Takahashi, A., Yahagi, N., et al. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.09.065 · Cited by 89
Effect of simvastatin on cholesterol metabolism in C2C12 myotubes and HepG2 cells, and consequences for statin-induced myopathy
Mullen, P. J., Lüscher, B., Scharnagl, H., Krähenbühl, S., & Brecht, K. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.12.007 · Cited by 88
Statin drug interactions and related adverse reactions
Bellosta, S., & Corsini, A. (2012) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2012.712959 · Cited by 111
Electronic healthcare databases for active drug safety surveillance: is there enough leverage?
Coloma, P. M., Trifirò, G., Schuemie, M. J., Gini, R., Herings, R. M. C., Hippisley‐Cox, J., Mazzaglia, G., Picelli, G., Corrao, G., Pedersen, L. H., et al. (2012) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3197 · Cited by 86
Destroy to Rebuild: The Connection Between Bone Tissue Remodeling and Matrix Metalloproteinases
Hardy, E., & Fernández-Patrón, C. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00047 · Cited by 86
Coenzyme Q10: is there a clinical role and a case for measurement?
Molyneux, S. L., Young, J. M., Florkowski, C. M., Lever, M., & George, P. M. (2008) · PubMed Central · Cited by 87
Effect of Ezetimibe and/or Simvastatin on Coenzyme Q10 Levels in Plasma
Berthold, H. K., Naini, A., Mauro, S. D., Hallikainen, M., Gylling, H. K., Krone, W., & Gouni‐Berthold, I. (2006) · Drug Safety · doi:10.2165/00002018-200629080-00007 · Cited by 87
Pharmacogenomics of cholesterol-lowering therapy
Schmitz, G., & Langmann, T. (2005) · Vascular Pharmacology · doi:10.1016/j.vph.2005.07.012 · Cited by 86
Statin-associated muscle symptoms—Managing the highly intolerant
Backes, J. M., Ruisinger, J. F., Gibson, C., & Moriarty, P. M. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.01.006 · Cited by 88

Authors: Thompson, P. D., Clarkson, P., & Karas, R. H.
Affiliations: Hartford Hospital (US)
ORCID: Thompson, Paul D.
Karas, Richard H.
Venue: JAMA
Publisher: American Medical Association (AMA)
Published: 2003-04-02
Volume: 289
Issue: 13
Pages: 1681
ISSN: 0002-9955 (ISSN-L)
0098-7484
DOI: 10.1001/jama.289.13.1681
OpenAlex: W2059078444
Cited by: 1,463
References: 114
Citations by year: 2026: 8 · 2025: 22 · 2024: 31 · 2023: 27 · 2022: 30 · 2021: 33 · 2020: 38 · 2019: 54 · 2018: 52 · 2017: 54 · 2016: 79 · 2015: 60 · 2014: 76 · 2013: 75 · 2012: 97
FWCI: 19.53
Type: journal article
Language: en
Open access: closed
Locations: JAMA (publishedVersion)
PubMed (publishedVersion)
ScholarWorks@UMassAmherst (University of Massachusetts Amherst) (submittedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
Health Sciences › Medicine › Surgery › Muscle and Compartmental Disorders
Keywords: statin-induced myopathy, statins, rhabdomyolysis, myositis, creatine kinase elevation, myalgia, statin withdrawal, adverse drug reactions, cerivastatin, gemfibrozil, drug interactions
MeSH terms: Anticholesteremic Agents, Creatine Kinase, Humans, Muscle Cramp, Muscular Diseases, Myositis, Rhabdomyolysis, Adverse Drug Reaction Reporting Systems, Muscle, Skeletal, Muscle Weakness, Hydroxymethylglutaryl-CoA Reductase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Statin-Associated Myopathy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks